and if the Hep B deal was close (presumably many months in the making) Benitec would not have reduced its staff by 50% and abandoned the preliminary/proprietary/exploratory work they initiated late last year and have been working on. These early pre-clinical programs would add more value to the company once the ddrnai platform is endorsed by a Hep B deal.
BLT Price at posting:
5.6¢ Sentiment: Buy Disclosure: Held
